Clarius Group, LLC - LYELL IMMUNOPHARMA INC ownership

LYELL IMMUNOPHARMA INC's ticker is LYEL and the CUSIP is 55083R104. A total of 95 filers reported holding LYELL IMMUNOPHARMA INC in Q4 2022. The put-call ratio across all filers is 0.74 and the average weighting 0.9%.

Quarter-by-quarter ownership
Clarius Group, LLC ownership history of LYELL IMMUNOPHARMA INC
ValueSharesWeighting
Q3 2023$586,777
-53.8%
399,1680.0%0.06%
-42.9%
Q2 2023$1,269,354
+3178.9%
399,168
+2333.4%
0.10%
+3166.7%
Q1 2023$38,713
+67817.5%
16,4040.0%0.00%
-40.0%
Q4 2022$57
-100.0%
16,4040.0%0.01%
-58.3%
Q3 2022$120,000
+12.1%
16,4040.0%0.01%
+9.1%
Q2 2022$107,000
-15.7%
16,4040.0%0.01%
+10.0%
Q1 2022$127,0000.0%16,4040.0%0.01%0.0%
Q4 2021$127,00016,4040.01%
Other shareholders
LYELL IMMUNOPHARMA INC shareholders Q4 2022
NameSharesValueWeighting ↓
MWG Management Ltd. 20,162,332$69,963,29235.72%
Orland Properties Ltd 15,093,969$52,376,07227.91%
Foresite Capital Management IV, LLC 10,000,000$34,700,00014.82%
MIC Capital Management UK LLP 3,060,569$10,620,1742.10%
Alphabet Inc. 5,865,125$20,351,9841.18%
HSG Holding Ltd 3,045,997$10,569,6101.07%
Artal Group S.A. 700,000$2,4290.14%
Eagle Health Investments LP 100,000$347,0000.08%
Virtus ETF Advisers LLC 39,345$136,5270.07%
BBR PARTNERS, LLC 164,041$569,2220.06%
View complete list of LYELL IMMUNOPHARMA INC shareholders